Video

Dr. Verhaak Discusses Genomic Characterization of Diffuse Lower Grade Gliomas

Roeland GW Verhaak, PhD, Assistant Professor, Department of Bioinformatics and Computational Biology, Division of Quantitative Sciences, The University of Texas MD Anderson Cancer Center, discusses a study that examined the comprehensive and integrative genomic characterization of diffuse lower grade gliomas.

Roeland GW Verhaak, PhD, Assistant Professor, Department of Bioinformatics and Computational Biology, Division of Quantitative Sciences, The University of Texas MD Anderson Cancer Center, discusses a study that examined the comprehensive and integrative genomic characterization of diffuse lower grade gliomas.

Verhaak says this project took nearly 300 tumor samples from patients with lower grade glimoa and performed extensive molecular characterization on these samples. Researchers analyzed the data, searching for subtypes.

An unsupervised analysis showed the same pattern in every data set analyzed, Verhaak says, leading researchers to classify samples into 3 groups: astrocytoma, oligodendroglioma, and oligo-astrocytoma.

Verhaak says these 3 groups are important because they share disease biology, which could help researchers in clinical trials. The study also found that one of the groups is wild type for IDH, which is very similar to patients with giloblastomas. Because of this, these lower grade gliomas should be treated like glioblastomas, Verhaak says.

<<<

View more from the 2014 Society for Neuro-Oncology Annual Meeting

Related Videos
Matthew J. Baker, PhD
Manmeet Ahluwalia, MD, MBA, FASCO
Albert Grinshpun, MD, MSc, head, Breast Oncology Service, Shaare Zedek Medical Center
Erica L. Mayer, MD, MPH, director, clinical research, Dana-Farber Cancer Institute; associate professor, medicine, Harvard Medical School
Stephanie Graff, MD, and Chandler Park, FACP
Mariya Rozenblit, MD, assistant professor, medicine (medical oncology), Yale School of Medicine
Maxwell Lloyd, MD, clinical fellow, medicine, Department of Medicine, Beth Israel Deaconess Medical Center
Neil Iyengar, MD, and Chandler Park, MD, FACP
Azka Ali, MD, medical oncologist, Cleveland Clinic Taussig Cancer Institute
Rena Callahan, MD, and Chandler Park, MD, FACP